Literature DB >> 28471604

A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.

Rinat Yerushalmi1,2, Shulamith Rizel3, Dalia Zoref3, Eran Sharon2, Ram Eitan4,5, Gad Sabah4, Ahuva Grubstein6, Yael Rafson6, Maya Cohen6, Ada Magen2, Iehudit Birenboim2, David Margel1,2,5, Rachel Ozlavo3, Aaron Sulkes1,2,5, Baruch Brenner1,2,5, Shlomit Perry3.   

Abstract

BACKGROUND: Women who carry the BRCA gene mutation have an up to 80% chance of developing cancer, primarily of breast and ovarian origin. Confirmation of carrier status is described by many women as an overwhelming, life-changing event. Healthy individuals harboring a BRCA mutation constitute a high risk population with unique needs, often overlooked by health authorities. As such, we felt the need to create a specialized service dedicated specifically to this high risk population. The clinic staff comprises an experienced multidisciplinary team of health professionals who can support the medical and emotional needs of this population. Since its inception in 2001 the clinic has served 318 women. The mean age of patients is 46 years. With a median follow-up of 46 months, 21 women have developed malignancies, including 17 breast cancers, 1 ovarian cancer and 3 additional cancers. All but one of the patients above the age of 40 underwent bilateral salpingo-oophorectomy (BSO). The median and mean ages at BSO were 46.5 and 48 years, respectively (range 33-68). However, only 28.3% underwent bilateral preventive mastectomy. A multidisciplinary clinic for BRCA mutation carriers provides a "home" for this unique population with unmet needs. The high rate of BSO in women before natural menopause indicates that both the medical community and this population are aware of international guidelines supporting this procedure. We believe that a dedicated clinic, with a multidisciplinary team, is likely to contribute to the health, quality of life and survival of BRCA carriers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28471604

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  5 in total

Review 1.  Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.

Authors:  Melissa Walker; Michelle Jacobson; Mara Sobel
Journal:  CMAJ       Date:  2019-08-12       Impact factor: 8.262

2.  Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.

Authors:  Adi Pomerantz; Daliah Tsoref; Ahuva Grubstein; Sonya Wadhawker; Yael Rapson; Itay Gadiel; Hadar Goldvaser; Ilan Feldhamer; Ariel Hammerman; Tzipora Shochat; Eran Sharon; Inbal Kedar; Rinat Yerushalmi
Journal:  Breast Cancer Res Treat       Date:  2022-04-07       Impact factor: 4.624

3.  GeneHome - a Novel Model to Deliver Care to Individuals with Genetic Predisposition to Cancer.

Authors:  Nadia Nocera Zachariah; Marie C Lee; Maxine D Chang; Colin Moore; Xia Wang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

4.  Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.

Authors:  Lauren Adolph; Ashley Warias; Jocelyn Stairs; Kelly Collins-McNeil; Lynette Penney; Katharina Kieser
Journal:  BMC Womens Health       Date:  2022-06-29       Impact factor: 2.742

5.  Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis.

Authors:  Guojiao Lu; Tao Lu; Jichen Pan; Ling Guo; Yingxin Pang; Peishu Liu
Journal:  Arch Gynecol Obstet       Date:  2020-11-20       Impact factor: 2.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.